| Sara Lynn Mccavitt, APRN, CNS, BC | |
|
18420 Sierra Vereda, Rio Verde, AZ 85263 | |
| (309) 453-1536 | |
| Not Available |
| Full Name | Sara Lynn Mccavitt |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Acute Care |
| Location | 18420 Sierra Vereda, Rio Verde, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891978672 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2100X | Clinical Nurse Specialist - Acute Care | 209005926 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sara Lynn Mccavitt, APRN, CNS, BC 18420 Sierra Vereda, Rio Verde, AZ 85263 Ph: (309) 453-1536 | Sara Lynn Mccavitt, APRN, CNS, BC 18420 Sierra Vereda, Rio Verde, AZ 85263 Ph: (309) 453-1536 |
News Archive
It is known that some people have the "delusional bug syndrome" and are convinced that bugs, worms, germs, or other creepy crawlers are infesting their skin and often see skin doctor after skin doctor to find out what is causing the infestation. Often, patients bring in samples of the insect and request a skin biopsy.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world's first treatment to impede the progression of Parkinson's disease following publication of research findings today in the journal Science Translational Medicine.
There remains a significant need for new and effective drugs that can be used to treat COVID-19.
› Verified 7 days ago